Northwest Bio Stock Price, News & Analysis

Northwest Biotherapeutics (OTCQB: NWBO) announced it has no banking relationship with Silicon Valley Bank (SVB) following SVB's shutdown. The company confirmed it had no funds deposited at SVB and believes it will not be affected by this situation, as it has diversified its banking relationships. NW Bio will monitor the situation and review its banking ties. The company is focused on developing DCVax® personalized immune therapies for cancer and has completed a Phase III trial for Glioblastoma multiforme. NW Bio aims to treat cancers more effectively than traditional therapies.

Northwest Biotherapeutics (NWBO) reported a strong turnout at its Annual Meeting on December 30, 2022, with 78% of shares voted. All six proposals received over 90% approval, including re-elections of directors and an increase of authorized common shares by 500 million. The company highlighted achievements in 2022, notably positive Phase 3 trial results for DCVax-L for Glioblastoma. Looking ahead, NWBO aims to secure a commercial manufacturing license and continue expanding operations in 2023, emphasizing ongoing progress in cancer immunotherapy.

Northwest Biotherapeutics has filed a lawsuit against prominent market makers, alleging they engaged in market manipulation via spoofing, causing significant stock price declines. The company claims these actions coincided with its efforts to raise funds for its groundbreaking DCVax personalized cancer vaccines. A notable incident occurred on May 10, 2022, resulting in an 82% drop in share price and a loss of $1.6 billion in market cap, despite positive clinical trial results. The lawsuit aims to hold these market makers accountable and restore transparency.

Northwest Biotherapeutics (NWBO) announced significant results from its Phase III trial of DCVax®-L for glioblastoma. The study demonstrated increased median survival and a 'long tail' of survival for both newly diagnosed and recurrent patients. Median Overall Survival (mOS) for newly diagnosed patients was 19.3 months, compared to 16.5 months for controls. For recurrent patients, mOS was 13.2 months versus 7.8 months. The trial met primary and secondary endpoints, encouragingly published in JAMA Oncology. Regulatory approval preparations for DCVax®-L are underway.

Northwest Biotherapeutics (NWBO) announced the approval from the UK MHRA for its Pediatric Investigation Plan (PIP) for DCVax-L, a personalized immune therapy targeting solid tumors. This PIP approval is critical for advancing the company's application for a Marketing Authorization Application (MAA) for adult patients. The PIP includes two clinical trials for pediatric high grade glioma patients, with a primary focus on overall survival compared to external controls. The company submitted the PIP in February 2022 and received final approval on August 17, 2022.

Northwest Biotherapeutics (NWBO) has submitted an application for a manufacturer's license to the Medicines and Healthcare Products Regulatory Agency (MHRA) for commercial production at its Sawston, UK facility. This application builds upon three licenses obtained in 2021. Key preparations involved developing 50 new standard operating procedures, validating equipment, and expanding cryostorage capabilities. Despite ongoing supply chain issues and personnel shortages, the company aims for license approval by year-end, which will enable commercial manufacturing of its DCVax® cellular therapies.

Northwest Biotherapeutics (OTCQB: NWBO) presented updates on its DCVax^®-L personalized immune therapies at the ASCO 2022 conference on June 4, highlighting advancements in manufacturing technology and scale-up preparations. Dr. Marnix Bosch discussed the Sawston, UK facility and a video on the clinical program was showcased. The company aims to treat aggressive solid tumor cancers effectively while minimizing toxicities compared to traditional therapies. The lead program targets Glioblastoma multiforme through a Phase III trial with 331 patients, reaching data lock recently.

Northwest Biotherapeutics (OTCQB: NWBO) presented findings on its DCVax^®-L at the Frontiers of Cancer Immunotherapy Conference on May 10, 2022. Dr. Paul Mulholland from University College Hospital highlighted data on the personalized immune therapy for glioblastoma, a lethal brain cancer. The company's lead program involves a 331-patient Phase III trial targeting newly diagnosed glioblastoma patients. This approach aims to offer effective cancer treatment with fewer toxicities compared to traditional therapies.

Northwest Biotherapeutics (NWBO) will present on May 10, 2022, at the Frontiers of Cancer Immunotherapy Conference, discussing its DCVax® personalized immune therapy for glioblastoma. This follows their notable Phase III trial involving 331 patients with newly diagnosed glioblastoma multiforme, which is recognized as a highly aggressive brain cancer. The company's approach aims at effective cancer treatment without the toxicities associated with conventional chemotherapies.